Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8652333 | 0.88 | PTGS2 (0.66) | PTGS2PTGS1PDE4B | |
| SCHEMBL8653702 | 0.87 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL8993358 | 0.80 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL8993482 | 0.76 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL6251471 | 0.76 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL8993420 | 0.75 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL8652881 | 0.75 | PTGS2 (0.60) | PTGS2PTGS1PDE4B | |
| SCHEMBL8652454 | 0.75 | PTGS2 (0.67) | PTGS2PTGS1PDE4B | |
| SCHEMBL8653276 | 0.74 | PTGS2 (0.66) | PTGS2PTGS1PDE4B | |
| SCHEMBL8651733 | 0.74 | PTGS2 (0.68) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0724566-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011883-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-05-04 | — | — | WO | disclosed |